Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 77

PubMed for Gene (Select 3817)

1.

Structure-function analyses of human kallikrein-related peptidase 2 establish the 99-loop as master regulator of activity.

Skala W, Utzschneider DT, Magdolen V, Debela M, Guo S, Craik CS, Brandstetter H, Goettig P.

J Biol Chem. 2014 Dec 5;289(49):34267-83. doi: 10.1074/jbc.M114.598201. Epub 2014 Oct 16.

2.

Analysis of androgen and anti-androgen regulation of KLK-related peptidase 2, 3, and 4 alternative transcripts in prostate cancer.

Lai J, An J, Nelson CC, Lehman ML, Batra J, Clements JA.

Biol Chem. 2014 Sep;395(9):1127-32. doi: 10.1515/hsz-2014-0149.

PMID:
25153393
3.
4.

Proteomic analysis of patient tissue reveals PSA protein in the stroma of benign prostatic hyperplasia.

O'Malley KJ, Eisermann K, Pascal LE, Parwani AV, Majima T, Graham L, Hrebinko K, Acquafondata M, Stewart NA, Nelson JB, Yoshimura N, Wang Z.

Prostate. 2014 Jun;74(8):892-900. doi: 10.1002/pros.22807. Epub 2014 Apr 7.

5.

The central role of EED in the orchestration of polycomb group complexes.

Cao Q, Wang X, Zhao M, Yang R, Malik R, Qiao Y, Poliakov A, Yocum AK, Li Y, Chen W, Cao X, Jiang X, Dahiya A, Harris C, Feng FY, Kalantry S, Qin ZS, Dhanasekaran SM, Chinnaiyan AM.

Nat Commun. 2014;5:3127. doi: 10.1038/ncomms4127.

6.

Genetic variation in KLK2 and KLK3 is associated with concentrations of hK2 and PSA in serum and seminal plasma in young men.

Sävblom C, Halldén C, Cronin AM, Säll T, Savage C, Vertosick EA, Klein RJ, Giwercman A, Lilja H.

Clin Chem. 2014 Mar;60(3):490-9. doi: 10.1373/clinchem.2013.211219. Epub 2013 Nov 22.

7.

Human kallikrein 2 (KLK2) promotes prostate cancer cell growth via function as a modulator to promote the ARA70-enhanced androgen receptor transactivation.

Shang Z, Niu Y, Cai Q, Chen J, Tian J, Yeh S, Lai KP, Chang C.

Tumour Biol. 2014 Mar;35(3):1881-90.

PMID:
24122203
8.

A possible mechanism behind autoimmune disorders discovered by genome-wide linkage and association analysis in celiac disease.

Östensson M, Montén C, Bacelis J, Gudjonsdottir AH, Adamovic S, Ek J, Ascher H, Pollak E, Arnell H, Browaldh L, Agardh D, Wahlström J, Nilsson S, Torinsson-Naluai Å.

PLoS One. 2013 Aug 2;8(8):e70174. doi: 10.1371/journal.pone.0070174. Print 2013.

9.

Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens: results from the European Randomized Study of Screening for Prostate Cancer section Rotterdam.

Carlsson S, Maschino A, Schröder F, Bangma C, Steyerberg EW, van der Kwast T, van Leenders G, Vickers A, Lilja H, Roobol MJ.

Eur Urol. 2013 Nov;64(5):693-9. doi: 10.1016/j.eururo.2013.04.040. Epub 2013 May 2.

10.

Genome-wide association study identifies genetic determinants of urine PCA3 levels in men.

Chen Z, Sun J, Kim ST, Groskopf J, Feng J, Isaacs WB, Rittmaster RS, Condreay LD, Zheng SL, Xu J.

Neoplasia. 2013 Apr;15(4):448-53.

11.

In-depth proteomic analyses of exosomes isolated from expressed prostatic secretions in urine.

Principe S, Jones EE, Kim Y, Sinha A, Nyalwidhe JO, Brooks J, Semmes OJ, Troyer DA, Lance RS, Kislinger T, Drake RR.

Proteomics. 2013 May;13(10-11):1667-71. doi: 10.1002/pmic.201200561. Epub 2013 Apr 23.

12.

Genome-wide association study identifies loci at ATF7IP and KLK2 associated with percentage of circulating free PSA.

Jin G, Zheng SL, Lilja H, Kim ST, Tao S, Gao Z, Young T, Wiklund F, Feng J, Isaacs WB, Rittmaster RS, Gronberg H, Condreay LD, Sun J, Xu J.

Neoplasia. 2013 Jan;15(1):95-101.

13.

Tissue kallikrein promotes cardiac neovascularization by enhancing endothelial progenitor cell functional capacity.

Yao Y, Sheng Z, Li Y, Yan F, Fu C, Li Y, Ma G, Liu N, Chao J, Chao L.

Hum Gene Ther. 2012 Aug;23(8):859-70. doi: 10.1089/hum.2011.123. Epub 2012 Apr 30.

14.

Interactions of pathological hallmark proteins: tubulin polymerization promoting protein/p25, beta-amyloid, and alpha-synuclein.

Oláh J, Vincze O, Virók D, Simon D, Bozsó Z, Tõkési N, Horváth I, Hlavanda E, Kovács J, Magyar A, Szũcs M, Orosz F, Penke B, Ovádi J.

J Biol Chem. 2011 Sep 30;286(39):34088-100. doi: 10.1074/jbc.M111.243907. Epub 2011 Aug 8.

15.

Exploratory study of a KLK2 polymorphism as a prognostic marker in prostate cancer.

Kohli M, Rothberg PG, Feng C, Messing E, Joseph J, Rao SS, Hendershot A, Sahsrabudhe D.

Cancer Biomark. 2010;7(2):101-8. doi: 10.3233/CBM-2010-0152.

16.

Validation of genome-wide prostate cancer associations in men of African descent.

Chang BL, Spangler E, Gallagher S, Haiman CA, Henderson B, Isaacs W, Benford ML, Kidd LR, Cooney K, Strom S, Ingles SA, Stern MC, Corral R, Joshi AD, Xu J, Giri VN, Rybicki B, Neslund-Dudas C, Kibel AS, Thompson IM, Leach RJ, Ostrander EA, Stanford JL, Witte J, Casey G, Eeles R, Hsing AW, Chanock S, Hu JJ, John EM, Park J, Stefflova K, Zeigler-Johnson C, Rebbeck TR.

Cancer Epidemiol Biomarkers Prev. 2011 Jan;20(1):23-32. doi: 10.1158/1055-9965.EPI-10-0698. Epub 2010 Nov 11.

17.

Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study.

Bailey SD, Xie C, Do R, Montpetit A, Diaz R, Mohan V, Keavney B, Yusuf S, Gerstein HC, Engert JC, Anand S; DREAM investigators.

Diabetes Care. 2010 Oct;33(10):2250-3. doi: 10.2337/dc10-0452. Epub 2010 Jul 13.

18.

Improved prediction of biochemical recurrence after radical prostatectomy by genetic polymorphisms.

Morote J, Del Amo J, Borque A, Ars E, Hernández C, Herranz F, Arruza A, Llarena R, Planas J, Viso MJ, Palou J, Raventós CX, Tejedor D, Artieda M, Simón L, Martínez A, Rioja LA.

J Urol. 2010 Aug;184(2):506-11. doi: 10.1016/j.juro.2010.03.144. Epub 2010 Jun 17.

PMID:
20620409
19.

Susceptibility loci associated with prostate cancer progression and mortality.

Gallagher DJ, Vijai J, Cronin AM, Bhatia J, Vickers AJ, Gaudet MM, Fine S, Reuter V, Scher HI, Halldén C, Dutra-Clarke A, Klein RJ, Scardino PT, Eastham JA, Lilja H, Kirchhoff T, Offit K.

Clin Cancer Res. 2010 May 15;16(10):2819-32. doi: 10.1158/1078-0432.CCR-10-0028. Epub 2010 May 11.

20.

Polymorphisms in innate immunity genes and risk of childhood leukemia.

Han S, Lan Q, Park AK, Lee KM, Park SK, Ahn HS, Shin HY, Kang HJ, Koo HH, Seo JJ, Choi JE, Ahn YO, Chanock SJ, Kim H, Rothman N, Kang D.

Hum Immunol. 2010 Jul;71(7):727-30. doi: 10.1016/j.humimm.2010.04.004. Epub 2010 May 16.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk